Holistic Prediction Framework for Pharmaceutical Portfolios
The preceding section established the conceptual foundations of the Decision Readiness Index (DRI) and Decision Readiness Levels (DRL) as diagnostic instruments for governing portfolio decisions under structural uncertainty. The present section describes the architecture of HPF-P (Holistic Portfolio Framework — Platform), the production system that operationalises these theoretical constructs i...
HPF-P is the reference implementation of the Holistic Portfolio Framework (HPF), providing a web-based platform for pharmaceutical portfolio decision support through DRI computation, DRL assignment, and strategy-appropriate optimization. This paper provides a technical overview of HPF-P: its architecture, API design, core algorithms, and deployment configuration. We describe the spec-driven dev...
Portfolio decision quality degrades when environmental entropy — the degree of unpredictability in the market system — exceeds the capacity of available information to characterize it. This paper formalizes the concept of environmental entropy in the context of pharmaceutical portfolio management and demonstrates its impact on Decision Readiness Index (DRI) dimension R5 (temporal stability). We...
The Decision Readiness Levels (DRL) framework prescribes one of five optimization strategies for each pharmaceutical portfolio segment, conditioned on that segment's Decision Readiness Index (DRI) score. This paper provides a complete specification of DRL-1 through DRL-5: the conditions under which each level is appropriate, the optimization methods employed at each level, the mathematical form...
Effective pharmaceutical portfolio optimization requires not only capable algorithms but also information of sufficient quality to support those algorithms. This paper provides a formal specification of the Decision Readiness Index (DRI), the core diagnostic component of the Holistic Portfolio Framework (HPF). DRI quantifies information sufficiency across five dimensions — data completeness (R1...
Pharmaceutical portfolio management operates at the intersection of scientific uncertainty, regulatory complexity, and market volatility. Traditional optimization approaches assume a stable, well-characterized information environment — an assumption that routinely fails in practice, particularly in emerging markets subject to geopolitical disruption. This paper introduces the Holistic Portfolio...